Tjip S van der Werf
Overview
Explore the profile of Tjip S van der Werf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
214
Citations
3823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dekkers B, Kerstjens H, Breisnes H, Leeming D, Anthony R, Frijlink H, et al.
J Infect Dis
. 2025 Feb;
PMID: 39932906
Background: Adjunctive host-directed therapies are investigated that modulate host immune responses to reduce excessive inflammation and prevent tissue damage in tuberculosis (TB). Macrolides, including azithromycin, were shown to possess anti-inflammatory...
2.
Klis S, Stienstra Y, Abass K, Abottsi J, Mireku S, Alffenaar J, et al.
Sci Rep
. 2024 Aug;
14(1):19963.
PMID: 39198495
Clarithromycin extended-release (CLA-ER) was used as companion drug to rifampicin (RIF) for Mycobacterium ulcerans infection in the intervention arm of a WHO drug trial. RIF enhances CYP3A4 metabolism, thereby reducing...
3.
Campbell J, Brode S, Barry P, Bastos M, Bonnet M, Guglielmetti L, et al.
Thorax
. 2023 Dec;
79(2):169-178.
PMID: 38135489
Background: Indicators of extensive disease-acid fast bacilli (AFB) smear positivity and lung cavitation-have been inconsistently associated with clinical rifampin-resistant/multidrug-resistant tuberculosis (RR/MDR-TB) outcomes. We evaluated the association of these indicators with...
4.
van den Born D, Martson A, Veringa A, Punt N, van der Werf T, Alffenaar J, et al.
Int J Antimicrob Agents
. 2023 Feb;
61(4):106750.
PMID: 36758777
Background: Voriconazole is an antifungal drug used for the treatment of invasive fungal infections. Due to highly variable drug exposure, therapeutic drug monitoring (TDM) has been recommended. TDM may be...
5.
Martson A, Da Silva Ferreira A, Veringa A, Liu L, Wardill H, Junier L, et al.
Ann Hematol
. 2023 Jan;
102(2):421-427.
PMID: 36648505
Gastrointestinal mucositis could potentially compromise drug absorption due to functional loss of mucosa and other pathophysiological changes in the gastrointestinal microenvironment. Little is known about this effect on commonly used...
6.
Veringa A, Bruggemann R, Span L, Biemond B, de Boer M, van den Heuvel E, et al.
Int J Antimicrob Agents
. 2023 Jan;
61(2):106711.
PMID: 36642232
Objectives: Voriconazole therapeutic drug monitoring (TDM) is recommended based on retrospective data and limited prospective studies. This study aimed to investigate whether TDM-guided voriconazole treatment is superior to standard treatment...
7.
Prins H, Duijkers R, Kramer G, Boerhout E, Rietema F, de Jong P, et al.
ERJ Open Res
. 2022 Jun;
8(2).
PMID: 35747233
Background: Acute exacerbations of COPD (AECOPD) and community acquired pneumonia (CAP) often coexist. Although chest radiographs may differentiate between these diagnoses, chest radiography is known to underestimate the incidence of...
8.
Abolhassani-Chimeh R, Akkerman O, Saktiawati A, Punt N, Bolhuis M, Subronto Y, et al.
Antimicrob Agents Chemother
. 2022 Jun;
66(7):e0000322.
PMID: 35727060
Pyrazinamide is one of the first-line antituberculosis drugs. The efficacy of pyrazinamide is associated with the ratio of 24-h area under the concentration-time curve (AUC) to MIC. The objective of...
9.
Ter Beek L, Bolhuis M, Jager-Wittenaar H, Brijan R, Sturkenboom M, Kerstjens H, et al.
BMJ Open
. 2022 Mar;
11(12):e049777.
PMID: 35344503
Objectives: Malnutrition is associated with a twofold higher risk of dying in patients with tuberculosis (TB) and considered an important potentially reversible risk factor for failure of TB treatment. The...
10.
Martson A, Sturkenboom M, Knoester M, van der Werf T, Alffenaar J, Hope W
J Antimicrob Chemother
. 2022 Feb;
77(2):466-473.
PMID: 35107143
Background: Cytomegalovirus (CMV) can cause severe disease, including rejection in transplant recipients. Ganciclovir and its oral prodrug valganciclovir have been used as first-line therapy for CMV disease in transplant recipients....